

primary studies - published RCT

Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.

Code: PM39762638

Year: 2025 Date: 1989

Author: Lanfranchi C

Study design (if review, criteria of inclusion for studies)

double-blind study

Participants

CF patients at least 12 years of age, with chronic respiratory tract colonization with *Pseudomonas aeruginosa* and hospitalized with a reduction in pulmonary function. experimental subjects: n = 8. control subjects: n = 8

Interventions

20% dextrose (control subjects: n = 8) or 100 mg/kg IVIG (Gamimune) (experimental subjects: n = 8) on days 1, 2, and 3; all patients received intravenous antibiotics and chest physiotherapy.

Outcome measures

clinical outcomes; pulmonary function, C3 level, circulating immune complex levels, side effects.

Main results

There were no differences between groups on admission; patients had moderate to severe disease as measured by Shwachman-Kulczycki scores and pulmonary function tests. Both groups improved clinically. The IVIG treatment was associated with significant increases in forced vital capacity and forced expiratory volume in 1 second (p less than 0.01) and with greater percent improvement in forced expiratory volume and forced expiratory flow (25% to 75%) (p less than 0.05). There was no effect on length of hospitalization (18.3 +/- 11.9 days control vs 17.6 +/- 6.5 experimental). The C3 level was decreased at discharge in IVIG-treated patients; circulating immune complex levels were unchanged. One patient in each group experienced side effects. There were no differences on follow-up at 6 weeks.

Authors' conclusions

IVIG infusion early in treatment for pulmonary exacerbations in cystic fibrosis patients with moderate to severe disease may be associated with greater improvement in pulmonary function than standard treatment alone.

<http://dx.doi.org/10.1007/s00408-024-00781-4>

See also

Lung. 2025 Jan 6;203(1):24. doi: 10.1007/s00408-024-00781-4.

Keywords

Bacterial Infections; Immunization; Immunoglobulin G; Immunoglobulins; Infection; Intravenous; pharmacological_intervention; *Pseudomonas aeruginosa*; *Pseudomonas*; Respiratory Tract Diseases; Respiratory Tract Infections; Exacerbation; Colonization;